Technology License with Transgene: Product TG4010 Interim Results
MELBOURNE, Australia, 24 January 2008--Virax Holdings Limited, (ASX: VHL), advises that Transgene SA of Strasbourg, France, reported that its therapeutic vaccine TG4010 showed promising preliminary Phase IIb data in advanced non-small cell lung cancer when used as an adjunct to first line chemotherapy. TG4010 uses Virax’s Co-X-Gene™ technology under the stated License Agreement between the Company and Transgene. Transgene said the trial confirmed the favourable safety profile of TG4010 when associated with chemotherapy and that based upon local evaluations, results are so far showing a positive trend in favour of the combination of TG4010 with the chemotherapy.
Virax’s CEO, Larry Ward, said “the data is encouraging. Transgene are making great progress with both this product and their therapeutic vaccine, TG4001, for the treatment of pathologies relating to human papilloma virus (HPV) infection that can lead to cervical cancer. The advancement of both Transgene products into late stage development exemplifies the intrinsic value of the Co-X-Gene™ technology intellectual property and the Transgene Sublicense. We look forward to the presentation by Transgene of the full trial data for TG4010 later in the year.”
The Transgene Press release is attached.
Virax, based in Melbourne, Australia, is a biopharmaceutical company engaged in the discovery and development of novel immunotherapeutic products for the treatment of chronic infectious diseases and cancer. The Company’s lead product, VIR201, an HIV/AIDS immunotherapeutic (therapeutic vaccine), recently cleared by the U.S. FDA to begin Phase II trials, has completed two successful clinical trials in Australia with additional international studies planned. The Company has also submitted an application to the South African regulatory authority (MCC) to conduct a Phase I/IIa trial of VIR201. Funding for the African trial has been contributed by a consortium of global and South African resource companies led by BHP Billiton.
In March 2007 Transgene (Eurolist Paris: FR0005175080) executed a Licence Agreement with the Company for access to Co-X-Gene™ technology for use in two of Transgene’s immunotherapeutic products. These are TG4001 – a treatment for pathologies relating to human papilloma virus (HPV) infection that can lead to cervical cancer - and TG4010 – a treatment for non-small cell lung cancer.
This was reported to the ASX in the Company’s announcement of 13 March 2007 and is referred to as the “Transgene Sub-licence”. Both TG4001 and TG4010 are in advanced development with Phase III trials of TG4001 planned for 2008 and Phase IIb studies of TG4010 currently underway. Transgene has licensed TG4001 to the pharmaceutical company Roche for treatment of HPV related pathologies.
Additional information about Virax is available at www.virax.com.au
For further information contact:
Dr Larry Ward John Morrison
CEO, Virax Holdings Limited CFO, Virax Holdings Limited
Melbourne, Australia Melbourne, Australia
(03) 9854 6230 (03) 9854 6230
Société anonyme au capital de 50.400.719 € – R.C. Strasbourg B 317 540 581 11, rue de Molsheim – 67082 Strasbourg Cedex (France) Tél : + 33 03 88 27 91 00 Fax : + 33 03 88 27 91 11
Posted: January 2008